Athersys

Athersys Cash Conversion

Delisted·Oct 1, 2026

The Cash Conversion Rate (OCF/Net Income) of Athersys (ATHXQ) as of Nov 20, 2026 is 81.27 %. In the previous year, Cash Conversion Rate (OCF/Net Income) was 87.61 % — a change of -7.24% (lower).

Cash Conversion

81.27 %

YoY

-7.24%

Last updated:

Cash Conversion Rate (OCF/Net Income) of Athersys is 2022 81.27 % . Cash Conversion Rate (OCF/Net Income) of Athersys was 2021 87.61 % . It decreases by -7.24% lower compared to the previous year.

The Athersys Cash Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion
Date
Cash Conversion
Jan 1, 2015
83.80 USD
Jan 1, 2016
71.25 USD
Jan 1, 2017
74.50 USD
Jan 1, 2018
54.98 USD
Jan 1, 2019
79.24 USD
Jan 1, 2020
78.47 USD
Jan 1, 2021
87.61 USD
Jan 1, 2022
81.27 USD
The Athersys Cash Conversion history
YEARCash ConversionYoY
81.27 %-7.24%
87.61 %+11.65%
78.47 %-0.96%
79.24 %+44.11%
54.98 %-26.20%
74.50 %+4.56%
71.25 %-14.97%
83.80 %-28.25%
116.80 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Athersys Stock analysis

What does Athersys do? Athersys, Inc. generates revenue through the development and commercialization of its MultiStem (invimestrocel) cell therapy, an allogeneic stem cell product candidate derived from adult bone marrow. The company focuses on late-stage clinical development for critical care, neurological conditions, inflammatory disorders, pulmonary conditions, and cardiovascular disease. Its lead product, MultiStem, is currently in Phase III clinical trials for ischemic stroke under the MASTERS-2 study. Athersys targets medical institutions and healthcare providers seeking innovative treatments for unmet medical needs in multiple disease areas. The company's primary product, MultiStem, is manufactured from human stem cells obtained from adult bone marrow and alternative tissue sources. It is designed to address conditions including critical care indications, neurological disorders, inflammatory and immune disorders, pulmonary conditions, and cardiovascular disease. Athersys conducts Phase III trials for ischemic stroke treatment, aiming to secure regulatory approval for broader market access. Revenue streams are expected to emerge post-approval through therapeutic product sales to hospitals and clinics. Athersys, Inc. operates in the biotechnology sector with a focus on regenerative medicine, leveraging its MultiStem platform to address unmet medical needs. The company's clinical development strategy centers on late-stage trials for ischemic stroke and other conditions, targeting healthcare providers and medical institutions as key customers. Commercialization of MultiStem will likely involve partnerships with healthcare systems for treatment protocols and patient access. Athersys is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Athersys stock

Cash Conversion Rate (OCF/Net Income) of Athersys is 81.27 % in 2022.

Cash Conversion Rate (OCF/Net Income) of Athersys changed from 87.61 % to 81.27 %, representing a -7.24% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Rate (OCF/Net Income) Athersys since 2006 – with annual values, charts, and detailed analysis.

Cash conversion measures how effectively net income converts to operating cash flow. Ratios above 100% indicate high-quality, cash-backed earnings.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Rate (OCF/Net Income)'s Athersys with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Rate (OCF/Net Income)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Rate (OCF/Net Income).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Athersys

All Key Metrics — Athersys